Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.205
+0.015 (0.68%)
Oct 24, 2025, 2:15 PM EDT - Market open
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $59.95M in the quarter ending June 30, 2025, with 92.73% growth. This brings the company's revenue in the last twelve months to $241.53M, up 636.99% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$241.53M
Revenue Growth
+636.99%
P/S Ratio
2.87
Revenue / Employee
$288,216
Employees
838
Market Cap
797.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IOVA News
- 6 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play - Seeking Alpha
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 - Seeking Alpha
- 2 months ago - Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewsWire
- 3 months ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz